company background image
ISKJ logo

Human Stem Cells Institute MISX:ISKJ Stock Report

Last Price

₽59.54

Market Cap

₽4.3b

7D

0%

1Y

-32.9%

Updated

05 Oct, 2022

Data

Company Financials

Public Joint-Stock Company "Human Stem Cells Institute"

MISX:ISKJ Stock Report

Market Cap: ₽4.3b

ISKJ Stock Overview

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia.

ISKJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends0/6

Public Joint-Stock Company "Human Stem Cells Institute" Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Human Stem Cells Institute
Historical stock prices
Current Share Price₽59.54
52 Week High₽177.00
52 Week Low₽52.52
Beta1.41
11 Month Change0%
3 Month Change1.43%
1 Year Change-32.86%
33 Year Change391.66%
5 Year Change388.03%
Change since IPO306.17%

Recent News & Updates

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

May 09
Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

Dec 25
Is Human Stem Cells Institute (MCX:ISKJ) Using Too Much Debt?

We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

Nov 19
We Wouldn't Rely On Human Stem Cells Institute's (MCX:ISKJ) Statutory Earnings As A Guide

Shareholder Returns

ISKJRU BiotechsRU Market
7D0%-2.0%-2.1%
1Y-32.9%-11.0%7.8%

Return vs Industry: ISKJ underperformed the Russian Biotechs industry which returned -10.3% over the past year.

Return vs Market: ISKJ exceeded the Russian Market which returned -38.2% over the past year.

Price Volatility

Is ISKJ's price volatile compared to industry and market?
ISKJ volatility
ISKJ Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.7%
10% most volatile stocks in RU Market9.8%
10% least volatile stocks in RU Market2.6%

Stable Share Price: ISKJ has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ISKJ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aPrikhodko Viktorovichhsci.ru

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.

Public Joint-Stock Company "Human Stem Cells Institute" Fundamentals Summary

How do Human Stem Cells Institute's earnings and revenue compare to its market cap?
ISKJ fundamental statistics
Market cap₽4.29b
Earnings (TTM)₽16.94m
Revenue (TTM)₽1.14b

253.1x

P/E Ratio

3.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISKJ income statement (TTM)
Revenue₽1.14b
Cost of Revenue₽424.68m
Gross Profit₽719.25m
Other Expenses₽702.31m
Earnings₽16.94m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin62.88%
Net Profit Margin1.48%
Debt/Equity Ratio103.9%

How did ISKJ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.